Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis
2015 · PLoS ONE · 18 citations
https://doi.org/10.1371/journal.pone.0127404
K
Ke Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
69
Papers
1.0K
Citations
17
h-index
23
i10-index
Ke Li is an academic researcher from Hebei General Hospital. The author has contributed to research in topics: Esophageal Cancer Research and Treatment & Gastric Cancer Management and Outcomes & Liver Disease and Transplantation. The author has an h-index of 17, co-authored 59 publications.
ORCID: 0000-0001-6973-6292Papers by this author
worksBoosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants
2024 · Journal of Controlled Release · 13 citations
https://doi.org/10.1016/j.jconrel.2024.05.010
Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
2022 · Frontiers in Oncology · 12 citations
https://doi.org/10.3389/fonc.2022.942678
Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response
2025 · Frontiers in Immunology · 1 citations
https://doi.org/10.3389/fimmu.2025.1689103
Negative impact of hyperglycaemia on mouse alveolar development
2017 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.5727033
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine
2024 · Expert Opinion on Drug Safety · 0 citations
https://doi.org/10.1080/14740338.2024.2419999
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat